Kinin-B1 Receptor Stimulation Promotes Invasion and is Involved in Cell-Cell Interaction of Co-Cultured Glioblastoma and Mesenchymal Stem Cells

Overview

Journal Sci Rep

Specialty Science

Date 2018 Jan 24

PMID 29358738

Citations 26

Authors

Mona N Oliveira

Micheli M Pillat

Helena Motaln

Henning Ulrich

Tamara T Lah

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) represents the most lethal brain tumour, and these tumours have very limited treatment options. Mesenchymal stem cells (MSC) are considered as candidates for advanced cell therapies, due to their tropism towards GBM, possibly affecting their malignancy, thus also representing a potential therapeutic vector. Therefore, we aimed to compare the effects of bone-marrow-derived versus adipose-tissue-derived MSC (BM-/AT-MSC) on heterogeneous populations of tumour cells. This cells' interplay was addressed by the in-vitro two-dimensional (monolayer) and three-dimensional (spheroid) co-culture models, using U87 and U373 GBM cell lines, expressing genotypically different mesenchymal transcriptome profiles. U87 cell low mesenchymal profile expressed high levels of kinin receptor 1 (B1R) and their invasion was greatly enhanced by the B1R agonist des-Arg-bradykinin upon BM-MSC co-culturing in 3D co-cultures. This correlated to significantly higher cell-cell interactions in U87/BM-MSC mixed spheroids. This was not observed with the U373 cells and not in AT-MSC co-cultures. Altogether, these data support the on-going exploration of B1R as target for adjuvant approach in GBM therapy. Secondly, the results emphasize the need for further careful exploration of the selectivity regarding the origin of MSC as potential candidates for cell therapies, particular in cancer, where they may adversely affect heterogeneous tumour cell populations.

Citing Articles

Sesquiterpene Lactones as Promising Anti-Glioblastoma Drug Candidates Exerting Complex Effects on Glioblastoma Cell Viability and Proneural-Mesenchymal Transition.

Markov A, Moralev A, Odarenko K Biomedicines. 2025; 13(1).

PMID: 39857717 PMC: 11761231. DOI: 10.3390/biomedicines13010133.

Fusion of tumor cells and mesenchymal stem/stroma cells: a source of tumor heterogeneity, evolution and recurrence.

Liu Z, Wang Y, Peng Z, Li H, Wang H, Wu Y Med Oncol. 2025; 42(2):52.

PMID: 39838167 DOI: 10.1007/s12032-024-02595-z.

Assessment of Radiolabelled Derivatives of R954 for Detection of Bradykinin B1 Receptor in Cancer Cells: Studies on Glioblastoma Xenografts in Mice.

Shukuri M, Onoe S, Karube T, Mokudai R, Wakui H, Asano H Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065752 PMC: 11279923. DOI: 10.3390/ph17070902.

Mesenchymal-Stem-Cell-Based Therapy against Gliomas.

Santillan-Guajan S, Shahi M, Castresana J Cells. 2024; 13(7.

PMID: 38607056 PMC: 11011546. DOI: 10.3390/cells13070617.

Current Knowledge about the Peritumoral Microenvironment in Glioblastoma.

Trevisi G, Mangiola A Cancers (Basel). 2023; 15(22).

PMID: 38001721 PMC: 10670229. DOI: 10.3390/cancers15225460.

References

Wolf K, Friedl P . Extracellular matrix determinants of proteolytic and non-proteolytic cell migration. Trends Cell Biol. 2011; 21(12):736-44. DOI: 10.1016/j.tcb.2011.09.006. View

Appaix F, Nissou M, van der Sanden B, Dreyfus M, Berger F, Issartel J . Brain mesenchymal stem cells: The other stem cells of the brain?. World J Stem Cells. 2014; 6(2):134-43. PMC: 3999771. DOI: 10.4252/wjsc.v6.i2.134. View

M Pawelek J . Fusion of bone marrow-derived cells with cancer cells: metastasis as a secondary disease in cancer. Chin J Cancer. 2014; 33(3):133-9. PMC: 3966146. DOI: 10.5732/cjc.013.10243. View

Goldenberg D, Zagzag D, Heselmeyer-Haddad K, Berroa Garcia L, Ried T, Loo M . Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo. Int J Cancer. 2011; 131(1):49-58. PMC: 3307948. DOI: 10.1002/ijc.26327. View

Quail D, Joyce J . The Microenvironmental Landscape of Brain Tumors. Cancer Cell. 2017; 31(3):326-341. PMC: 5424263. DOI: 10.1016/j.ccell.2017.02.009. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Wang R, Sun X, Wang C, Hu P, Chu C, Liu S . Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression. PLoS One. 2012; 7(8):e42653. PMC: 3411834. DOI: 10.1371/journal.pone.0042653. View

Mercapide J, Rappa G, Lorico A . The intrinsic fusogenicity of glioma cells as a factor of transformation and progression in the tumor microenvironment. Int J Cancer. 2011; 131(2):334-43. DOI: 10.1002/ijc.26361. View

Overholtzer M, Mailleux A, Mouneimne G, Normand G, Schnitt S, King R . A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell. 2007; 131(5):966-79. DOI: 10.1016/j.cell.2007.10.040. View

10.

Mohr M, Zanker K, Dittmar T . Cancer (stem) cell differentiation: An inherent or acquired property?. Med Hypotheses. 2015; 85(6):1012-8. DOI: 10.1016/j.mehy.2015.08.017. View

11.

Kashuba E, Bailey J, Allsup D, Cawkwell L . The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers. 2013; 18(4):279-96. DOI: 10.3109/1354750X.2013.787544. View

12.

Trujillo C, Negraes P, Schwindt T, Lameu C, Carromeu C, Muotri A . Kinin-B2 receptor activity determines the differentiation fate of neural stem cells. J Biol Chem. 2012; 287(53):44046-61. PMC: 3531721. DOI: 10.1074/jbc.M112.407197. View

13.

Iwadate Y . Epithelial-mesenchymal transition in glioblastoma progression. Oncol Lett. 2016; 11(3):1615-1620. PMC: 4774466. DOI: 10.3892/ol.2016.4113. View

14.

Stewart J, Gera L, Chan D, Bunn Jr P, York E, Simkeviciene V . Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol. 2002; 80(4):275-80. DOI: 10.1139/y02-030. View

15.

Marceau F, Regoli D . Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov. 2004; 3(10):845-52. DOI: 10.1038/nrd1522. View

16.

Dittmar T, Zanker K . Tissue Regeneration in the Chronically Inflamed Tumor Environment: Implications for Cell Fusion Driven Tumor Progression and Therapy Resistant Tumor Hybrid Cells. Int J Mol Sci. 2015; 16(12):30362-81. PMC: 4691180. DOI: 10.3390/ijms161226240. View

17.

Rhee K, Lee J, Eom Y . Mesenchymal Stem Cell-Mediated Effects of Tumor Support or Suppression. Int J Mol Sci. 2015; 16(12):30015-33. PMC: 4691158. DOI: 10.3390/ijms161226215. View

18.

Bryukhovetskiy I, Shevchenko V . Molecular mechanisms of the effect of TGF-β1 on U87 human glioblastoma cells. Oncol Lett. 2016; 12(2):1581-1590. PMC: 4950569. DOI: 10.3892/ol.2016.4756. View

19.

Motaln H, Koren A, Gruden K, Ramsak Z, Schichor C, Lah T . Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance. Oncotarget. 2015; 6(38):40998-1017. PMC: 4747385. DOI: 10.18632/oncotarget.5701. View

20.

Schichor C, Albrecht V, Korte B, Buchner A, Riesenberg R, Mysliwietz J . Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Exp Neurol. 2012; 234(1):208-19. DOI: 10.1016/j.expneurol.2011.12.033. View